1st Quarter - Report

VIATRIS INC. for VIATRIS INC

Firm
Client
Income
—
Expenses
$680,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

S. 501 Fair Prescription Drug Competition Act, REMS (Risk Evaluation and Mitigation Strategies)

LobbyistCovered position, as disclosed
RICHARD WHELAND —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 501 (111th)

Health Issues HCR

H.R. 573, Bill to prohibit authorized generics during period of exclusivity; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; S. 369 (Preserve Access to Affordable Generics Act); H.R. 3962, the Affordable Health Care for America Act, Sections 1741, 2501, 2502, 2573; H.R. 3590, the Patient Care and Affordable Protection Act, Sections 2501, 2503, 7101

LobbyistCovered position, as disclosed
DAVID RICE —
RICHARD WHELAND —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 3962 (111th), H.R. 3590 (111th), H.R. 573 (111th), S. 369 (111th), H.R. 1706 (111th)

Budget/Appropriations BUD

Approps/OGD funding

LobbyistCovered position, as disclosed
RICHARD WHELAND —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

PL 110-275, Medicare Improvement for Patients and Providers Act of 2008, Section 203, pharmacy reimbursement under Medicaid

LobbyistCovered position, as disclosed
RICHARD WHELAND —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.